Levodopa / opicapone as a complement to STN-DBS in clinical practice. A retrospective single-centre analysis.
These results indicate a clinical phenotype characterised by more motor fluctuations requiring a more stable dopamine replacement therapy to address the patients' disease biology. In these cases, levodopa + COMT inhibition by opicapone represents a therapeutic approach but determination of the potential clinical benefit requires further prospective studies.
Authors
- Daniel Weiß (ORCID: https://orcid.org/0000-0003-0447-7132)
- Alireza Gharabaghi (ORCID: https://orcid.org/0000-0002-9782-5281)
- Idil Cebi (ORCID: https://orcid.org/0000-0002-1458-9173)
- Philipp Klocke (ORCID: https://orcid.org/0000-0003-0868-5270)
- M. Loeffler (ORCID: https://orcid.org/0000-0002-0267-2762)
Institutions
- Hertie Institute for Clinical Brain Research (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- eNeurologicalSci
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1016/j.ensci.2024.100530
- Primary Topic
- Neurological disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação Bial